Literature DB >> 10525383

Adenovirus-mediated p53 growth inhibition of ovarian cancer cells is independent of endogenous p53 status.

J K Wolf1, G B Mills, L Bazzet, R C Bast, J A Roth, D M Gershenson.   

Abstract

OBJECTIVE: The aim of this study was to determine the effect of transfection of adenovirus-mediated wild-type p53 into ovarian cancer cells with both wild-type and mutant endogenous p53. STUDY
DESIGN: Eight human ovarian cancer cell lines were used: three with p53 mutations, one that is p53 null, and four with wild-type p53. The recombinant p53 adenovirus (Adp53) contains the cytomegalovirus promoter, wild-type p53 cDNA, and SV40 polyadenylation signal in a minigene cassette inserted into the E1-deleted region of modified Ad5. The transduction efficiency of cells was assessed using a beta-gal-containing adenovirus. Cell-counting assays were used to evaluate the effect of transfection with Adp53 on the growth of cells. P53 expression was evaluated using Western blot. Cell cycle analysis and apoptosis studies were done using a tunnel-based assay and fluorescent activated cell sorting.
RESULTS: Transduction efficiencies varied between cell lines. More than 90% growth inhibition occurred in seven of eight cell lines after infection with adenovirus-mediated p53 if a viral dose leading to at least 50% of cells infected was used. Regardless of endogenous p53 status, apoptosis occurred in cells infected with p53.
CONCLUSIONS: Ovarian cancer cells are growth inhibited by transfection with adenovirus-mediated p53 regardless of their endogenous p53 status. Growth inhibition is related to transduction efficiency. Copyright 1999 Academic Press.

Entities:  

Mesh:

Year:  1999        PMID: 10525383     DOI: 10.1006/gyno.1999.5565

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  8 in total

1.  Molecular profiling uncovers a p53-associated role for microRNA-31 in inhibiting the proliferation of serous ovarian carcinomas and other cancers.

Authors:  Chad J Creighton; Michael D Fountain; Zhifeng Yu; Ankur K Nagaraja; Huifeng Zhu; Mahjabeen Khan; Emuejevoke Olokpa; Azam Zariff; Preethi H Gunaratne; Martin M Matzuk; Matthew L Anderson
Journal:  Cancer Res       Date:  2010-02-23       Impact factor: 12.701

2.  Calpain-mediated processing of p53-associated parkin-like cytoplasmic protein (PARC) affects chemosensitivity of human ovarian cancer cells by promoting p53 subcellular trafficking.

Authors:  Michael G Woo; Kai Xue; Jiayin Liu; Heidi McBride; Benjamin K Tsang
Journal:  J Biol Chem       Date:  2011-11-23       Impact factor: 5.157

Review 3.  Drug delivery and transport to solid tumors.

Authors:  Seong Hoon Jang; M Guillaume Wientjes; Dan Lu; Jessie L S Au
Journal:  Pharm Res       Date:  2003-09       Impact factor: 4.200

Review 4.  [The use of p53 as a tool for human cancer therapy].

Authors:  V P Almazov; D V Kochetkov; P M Chumakov
Journal:  Mol Biol (Mosk)       Date:  2007 Nov-Dec

5.  Overexpression of forkhead box protein M1 (FOXM1) in ovarian cancer correlates with poor patient survival and contributes to paclitaxel resistance.

Authors:  Fung Zhao; Michelle K Y Siu; LiLi Jiang; Kar Fai Tam; Hextan Y S Ngan; Xiao Feng Le; Oscar G W Wong; Esther S Y Wong; Ana R Gomes; Laura Bella; Pasarat Khongkow; Eric W-F Lam; Annie N Y Cheung
Journal:  PLoS One       Date:  2014-11-20       Impact factor: 3.240

6.  High-grade serous ovarian cancer cell lines exhibit heterogeneous responses to growth factor stimulation.

Authors:  Danielle L Bourgeois; Karl A Kabarowski; Veronica L Porubsky; Pamela K Kreeger
Journal:  Cancer Cell Int       Date:  2015-12-07       Impact factor: 5.722

7.  Effects of recombinant human adenovirus-p53 on the regression of hepatic fibrosis.

Authors:  Yehong Liu; Puye Yang; Na Chen; Shumei Lin; Min Liu
Journal:  Int J Mol Med       Date:  2016-08-26       Impact factor: 4.101

8.  Differential suppression of human cervical cancer cell growth by adenovirus delivery of p53 in vitro: arrest phase of cell cycle is dependent on cell line.

Authors:  Woong Shick Ahn; You Jin Han; Su Mi Bae; Tae-Hyung Kim; Min Seok Rho; Joon Mo Lee; Sung Eun Namkoong; Yong Seok Park; Chong Kook Kim; Jeong-Im Sin
Journal:  Jpn J Cancer Res       Date:  2002-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.